CASI
Pharmaceuticals Inc. (Nasdaq: CASI) received orphan drug designation from
the European Medicines Agency for ENMD-2076 to treat hepatocellular
carcinoma. The stock price rose 41 cents to close at $1.43.
CASI Pharmaceuticals receives orphan drug designation
October 14, 2015 at 18:26 PM EDT
